IncCRLA Enhanced Chemoresistance in Lung Adenocarcinoma That Underwent epithelial-mesenchymal Transition

Weili Min  
Xi’an Jiaotong University

Liangzhang Sun  
Xi’an Jiaotong University

Xiao Gao  
Xi’an Jiaotong University

Shuqun Zhang  
Xi’an Jiaotong University

Yang Zhao (✉ szhaoy@126.com)  
Second affiliated hospital of Xi’an Jiaotong University

Research

Keywords: EMT, chemotherapy resistance, lung adenocarcinoma, IncRNA

DOI: https://doi.org/10.21203/rs.3.rs-35582/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

EMT confers increased metastatic potential and the resistance to chemotherapies to cancer cells. However, the precise mechanisms of EMT-related chemotherapy resistance remain unclear.

Methods

Anticancer effects were determined by MTT, soft agar, cell cycle, propidium iodide and Annexin V analysis. The effect of drugs on tumor growth was assessed using patient-derived xenograft model and nude mice model. Morphology of tumor cells were observed by phase contrast microscopy. Proteins interactions were tested by western blot and coimmunoprecipitation. Immunohistochemistry and LNA ISH were performed to determine protein and IncRNA expression. Candidate IncRNA was screened out by microarray.

Results

c-Src-mediated Caspase-8 phosphorylation essential for EMT in lung adenocarcinoma cell lines preferentially occurs in cells with the mesenchymal phenotype, resulting in chemoresistance to cisplatin plus paclitaxel in patients with resectable lung adenocarcinoma and a significantly worse 5-year PFS. Cisplatin killed lung adenocarcinoma cells regardless of Caspase-8. Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8, during which FADD interacted with RIPK1 to activate RIPK1/RIPK3/MLKL signaling axis. Accompanied with c-Src-mediated Caspase-8 phosphorylation to trigger EMT, a novel IncRNA named IncCRLA was markedly upregulated and inhibited RIPK1-induced necroptosis by impairing RIPK1-RIPK3 interaction via binding to the intermediate domain of RIPK1. Dasatinib mitigated c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in mesenchymal-like lung adenocarcinoma cells treated with paclitaxel, while c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.

Conclusions

c-Src-Caspase-8 interaction initiates EMT and chemoresistance via Caspase-8 phosphorylation and IncCRLA expression, to which the dasatinib/paclitaxel liposome+siFLIP regimen was lethal.

Highlights

Highlights: 1. c-Src-mediated Caspase-8 phosphorylation in lung adenocarcinoma was required for EMT to facilitate chemoresistance to paclitaxel. 2. Caspase-8 phosphorylation or deficiency induced the paclitaxel-mediated necroptosis in lung adenocarcinoma. 3. Activation of IncRNA-related chemotherapy resistance in lung adenocarcinoma (IncCRLA) during c-Src-Caspase-8-induced EMT inhibited RIPK1-induced
necroptosis. A novel therapeutic agent, paclitaxel liposome encapsulating siRNA specific for c-FLIP combined with clearly sensitized the mesenchymal-like lung adenocarcinoma cells.

**Background**

In both the United States and P.R. China, lung cancer is not only the leading cause of cancer death by far but also the second leading cause of death from any cause after heart disease based on calculations from published data [1, 2]. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers with a markedly increased incidence of lung adenocarcinoma [3]. The 5-year overall survival rate for lung adenocarcinoma is only 17% because, in a startlingly high proportion of patients with lung adenocarcinoma, the disease has already metastasized at the initial diagnosis or recurs after initial surgery or radiotherapy [4, 5]. Lung adenocarcinoma is generally incurable because it will either have an intrinsic resistance to chemotherapy or develop acquired resistance after an initial response [6, 7]. Therefore, identifying molecular determinants of the resistance to chemotherapy in lung adenocarcinoma is necessary to improve its clinical efficacy.

Despite significant advances in diagnosing and treating lung adenocarcinoma, metastasis persists as a barrier to successful treatment and the main cause of cancer-related death [8-10]. Epithelial-mesenchymal transition (EMT), wherein epithelial cells depolarize, lose their cell–cell contacts, and gain an elongated, fibroblast-like morphology, is a potential mechanism by which tumor cells acquire metastatic features [11, 12]. The prometastatic role of EMT in various human cancers was recently challenged by the research groups of Kari R. Fisher and Xiaofeng Zheng, who both stated that EMT was not a rate-limiting step for metastasis but rather inadvertently conferred resistance to antiproliferative drugs such as gemcitabine [6, 13]. Notwithstanding, EMT-induced resistance to antitumor drugs remains an integral characteristic of lung adenocarcinoma. We observed that phosphorylation of Caspase-8 by c-Src induced both EMT through c-Src overactivation and resistance to chemotherapy through necroptosis [14]. Hence, the mechanism by which phosphorylated Caspase-8 confers resistance to chemotherapy appeared to be worth pursuing. In our study, c-Src-mediated Caspase-8 phosphorylation essential for the EMT in lung adenocarcinoma cell lines was preferential for the mesenchymal phenotype, leading to chemoresistance to cisplatin plus paclitaxel in patients with resectable lung adenocarcinoma. Cisplatin rendered lung adenocarcinoma cells susceptible to death regardless of Caspase-8, while the paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of Caspase-8. During this necroptosis activation, FADD interplayed with RIPK1 to activate the RIPK1/RIPK3/MLKL signaling axis. Concomitant with c-Src-mediated Caspase-8 phosphorylation to trigger EMT, a brand-new lncRNA, named lncCRLA, was markedly upregulated to inhibit RIPK1-induced necroptosis by impairing the RIPK1-RIPK3 interaction via binding to the intermediate domain of RIPK1. Dasatinib, a c-Src inhibitor, impaired c-Src-mediated phosphorylation of Caspase-8-induced EMT and enhanced necroptosis in paclitaxel-treated mesenchymal-like lung adenocarcinoma cells. Intriguingly, c-FLIP knockdown predominantly sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel+dasatinib.
Methods

Ethics approval and consent to participate

The procedures of this study, including 7 references, were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University. The experiments were performed upon receiving written consent from each subject. The study methodologies conformed to the standards set by the Declaration of Helsinki.

Reagents and drugs

Paclitaxel (Bristol-Myers Squibb) was purchased from Sigma for cell culture and animal studies at concentrations of 100 nM, 200 nM, and 400 nM. An original solution of cisplatin (Pfizer) at a concentration of 1 M was stored at 4°C and freshly dissolved in culture medium before use. Dasatinib (Sprycel, Bristol-Myers Squibb) was dissolved in dimethyl sulfoxide (DMSO) and used at a final concentration of $10^{-6}$ M. z-VAD-fmk (50 mM) and z-IETD-fmk (50 mM) were obtained from Alexis Biochemicals. 3-Methyladenine (3-MA, 1 mg/10 ml) was purchased from InvivoGen. Necrostatin-1 (nec-1, 10 mM) was generously gifted by Chen Huang from the Department of Cell Biology, Xi’an Jiaotong University, Shaanxi Province, P.R. China.

Cell culture, DNA/shRNA transfection and stable cell line generation

Lung adenocarcinoma cell lines, including A549, National Cancer Institute (NCI)-H522 and H23, were kind gifts from Chen Huang from the Department of Cell Biology, Xi’an Jiaotong University, Shaanxi Province, P.R. China. H1395, H1437, H1573, H920, H2935, H1299, H2030, H2405, H647 and H838 cells were purchased from American Type Culture Collection (ATCC) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS, HyClone) and penicillin/streptomycin/L-glutamine (Sigma). The cell lines in our study were authenticated by short tandem repeat (STR) analysis. To observe the morphologic features of EMT, we cultured cells for 5 days on fibronectin (10 μg/ml)-coated dishes. Cells were assayed for expression and viability following treatment with reagents or drugs at 2 days after attachment to the fibronectin-coated dishes. Knockdown of RIPK1, FADD, c-FLIP, Caspase-8, c-Src or lncCRLA was performed using lentivirus-delivered short hairpin RNAs (shRNAs) constructed by GenePharma (shRNAs targeting c-FLIP and IncCRLA corresponded to the siRNAs below; Shanghai, China). Following lentiviral transfection, stable cell lines were selected via culturing in the presence of 500 μg/ml G418 (Gibco). The open reading frames of genes of interest, including wild-type Caspase-8, wild-type RIPK1, death domain-deleted RIPK1, intermediate domain-deleted RIPK1, kinase domain-deleted RIPK1, c-Src, and constitutively active c-Src (Src Y527F), were cloned into the MSCV-IRES-zeo plasmid with a hemagglutinin (HA) tag to allow the expression of HA-tagged proteins. The subsequent DNA was transfected into packaging cells. Virus-containing supernatants were removed, and debris was pelleted by centrifugation. Target cells were cultured in virus-containing supernatants for 48 hr before selection for a stable cell line with 10 mg/ml zeocin (Invitrogen) for 14 days.
Results

c-Src-induced Caspase-8 phosphorylation was required for EMT in lung adenocarcinoma cell lines.

In lung adenocarcinoma, the molecular characteristics of EMT could be divided into mesenchymal, epithelial, and intermediate phenotypes based on the expression of E-cadherin (E-cad) and Vimentin (Vim) [15]. We distinguished our lung adenocarcinoma cell lines as having epithelial or mesenchymal properties (described as epithelial-like and mesenchymal-like cells, respectively). Prior work showed that phosphorylation of Caspase-8 at tyrosine 380 (p-Casp8) by c-Src enhances c-Src activation (p-Src) and triggers EMT [14, 16, 17]. Thus, it was likely that p-Casp8 could function as a biomarker for EMT in lung adenocarcinoma. We initially investigated the expression levels of c-Src and Caspase-8 in lung adenocarcinoma cells, which showed ubiquitous expression of both proteins; however, Caspase-8 expression was absent in H522 cells (Figs 1A and 1B). p-Casp8 was present in the mesenchymal-like lung adenocarcinoma cell lines with lower E-cad levels and higher Vim levels (Fig S1A), whereas no p-Casp8 was observed in the epithelial-like cell lines with higher E-cad levels and lower Vim levels (Fig S1B). There was remarkably lower c-Src expression in the epithelial-like cell lines than in the mesenchymal-like cell lines (Figs 1A and 1B). A549 cells transfected with control shRNA and H522 cells with ectopic expression of Caspase-8 presented the mesenchymal-like morphology with E-cad downregulation and Vim upregulation (A549+Control/H522+Casp8: mesenchymal-like; Figs S1C, 1C and 1D), whereas A549 cells with c-Src/Caspase-8 knockdown and H522 cells transfected with control vector presented epithelial properties (A549+Casp8/Src shRNA and H522+Control: epithelial-like; Figs S1C, 1C and 1D). Taken together, c-Src-induced Caspase-8 phosphorylation was required for EMT in lung adenocarcinoma cell lines.

To further clarify the role of c-Src in EMT, we ectopically expressed c-Src in epithelial-like lung adenocarcinoma cell lines with Caspase-8 expression (H1395, H1437, H1573, H1693, and H1568). The molecular and morphological characteristics in cells were more mesenchymal-like; these changes were concomitant with markedly increased levels of p-Casp8 and p-Src in the epithelial-like lung adenocarcinoma cell lines transfected with c-Src (Figs 1E, 1F and S1D). Furthermore, upregulation of c-Src induced more aggressive behavior in the epithelial-like cell lines (Figs 1G, S1E and S1F). It was noteworthy that c-Src was mildly activated in H522 cells lacking Caspase-8. The results suggested that the expression level of c-Src was associated with its basic activity to initiate Caspase-8 phosphorylation in lung adenocarcinoma.

c-Src-induced Caspase-8 phosphorylation was associated with the mesenchymal phenotype and contributed to chemoresistance in lung adenocarcinoma.

As the antiapoptotic role of p-Casp8 in several human tumors has been described [16], we sought to uncover the underlying mechanism by which p-Casp8-induced EMT restricted the clinical efficacy of the TP regimen in lung adenocarcinoma. It was a tremendous challenge to assess the epithelial/mesenchymal status of tumor tissues due to the heterogeneity in the diverse domains of the tumor. According to our outcomes and a prior report [15, 17], Vim and E-cad were confirmed as
appropriate biomarkers to predict the epithelial/mesenchymal properties of lung adenocarcinoma tissues. We initially assessed the levels of p-Casp8, Vim and E-cad through immunohistochemistry (IHC) in 40 patients with operable lung adenocarcinoma (Figs 2A, 2B and 2C; Table 1). p-Casp8 was associated with upregulated Vim and downregulated E-cad expression and with mesenchymal-like properties (Figs S2A, S2B and S2C), indicating that p-Casp8 could serve as a biomarker for EMT in lung adenocarcinoma tissues.

We next investigated the relationship between p-Casp8 level and the response rate to neoadjuvant chemotherapy in patients with resectable lung adenocarcinoma. A total of 109 patients were divided into p-Casp8-positive (n = 52) and p-Casp8-negative (n = 57) groups (Table S1). Patients with p-Casp8-positive lung adenocarcinoma presented significantly lower complete response (CR) and partial response (PR) rates following 2 neoadjuvant cycles of TP regimen (Fig 2D). In addition to the lower response rate to the TP regimen, the p-Casp8-positive cohort exhibited a remarkably worse 5-year PFS (p < 0.05, Fig 2E). Next, we recruited 20 patients with metastatic lung adenocarcinoma to examine the levels of p-Casp8. As shown in Table S2, patients with p-Casp8-negative lung adenocarcinoma exhibited a better response to the TP regimen than did patients with p-Casp8-positive lung adenocarcinoma. Based on CT images, there was a significant reduction in lesion size in the p-Casp8-negative group (Figs S2D and S2E). Then, 7 pairs of pretreatment and posttreatment biopsies were acquired, and we detected markedly increased p-Casp8 following two cycles of the TP regimen (Fig S2F). Moreover, the proportion of p-Casp8-positive cells was sharply increased following TP regimen administration (Fig S2G). Taken together, the results showed that in lung adenocarcinomas, p-Casp8 was associated with mesenchymal-like properties and contributed to disease progression by increasing the resistance to the TP regimen.

**c-Src-mediated Caspase-8 phosphorylation inhibited cell death of lung adenocarcinoma through the paclitaxel-triggered necroptosis during EMT.**

Next, we sought to determine the underlying mechanism for the difference in response to the TP regimen in p-Casp8-positive and p-Casp8-negative lung adenocarcinoma. A549 cells were stably transfected with lentiviral control, Caspase-8, or c-Src shRNA (A549+Control: mesenchymal-like; A549+Caspase-8/c-Src shRNA: epithelial-like). Cisplatin caused A549 cell death in the time- and concentration-dependent manner regardless of c-Src or Caspase-8 expression (Fig 3A). Cisplatin might not contribute to resistance to the TP regimen in p-Casp8-positive lung adenocarcinoma. Comparing with the mesenchymal-like A549 cells, the antitumor efficacy of paclitaxel in A549 cells transduced with c-Src shRNA was most potent and was dependent on the intervention time and drug concentration (Fig 3B), while Caspase-8 knockdown in A549 cells strikingly yielded a marked increase in paclitaxel-mediated cell death (Fig 3B). These data were further supported by *in vivo* xenograft and *in vitro* colony assays (Figs S3A and S3B). Then, we analyzed the response to the TP regimen in the lung adenocarcinoma tissues from p-Casp8-negative patients, who were divided into two groups according to IHC testing of Caspase-8 and c-Src: Casp8(+) c-Src(-) (n = 20) and Casp8(-) c-Src(+) (n = 37), (Fig S3F). The response to the TP regimen in Casp8(+) c-Src(-) patients was significantly superior to that in Casp8(-) c-Src(+) patients (Figs S3G and S3H). It indicated that
Caspase-8 yielded more antitumor activities relative to phosphorylated or lacking Caspase-8 in response to paclitaxel treatment in lung adenocarcinoma.

Paclitaxel interferes with mitotic spindle dynamics to induce an extended G2/M arrest, which can lead to cell death [18]. Consistently, paclitaxel significantly enhanced G2/M arrest of A549 cells (Fig S3C). To decipher the paclitaxel-triggered cell death mechanism in lung adenocarcinoma, the inhibitors specific for RIPK1-induced necroptosis (nec-1), Caspase-8-induced apoptosis (z-IETD-fmk), pan-Caspase-induced apoptosis (z-VAD-fmk), and autophagy (3-MA) were applied. As shown in Figure 3C, paclitaxel committed approximately 70% of c-Src-silenced A549 cells to death as indicated by a marked increase in the number of Annexin V-positive cells (apoptotic cells); this activity was completely blocked by either z-IETD-fmk or z-VAD-fmk alone (Figs 3C and S3D). Prior work reported that blocking Caspase-8-induced apoptosis led to cell death dependent on RIPK1 and RIPK3, which was defined as necroptosis following sensing death [19, 20]. Consistently, paclitaxel gave rise to a marked increase in the proportion of propidium iodide (PI)-positive cells (necrotic cells) in A549 cells transduced with Caspase-8 shRNA (Fig 3C), that was prevented by the addition of nec-1 (Fig S3D). Notably, the mesenchymal-like A549 cells (A549 + Control) with Caspase-8 phosphorylation were resistant to paclitaxel-induced cell death; however, treatment with nec-1 restored a smaller amount of cell death compared with that in A549 cells transduced with Caspase-8 shRNA (Figs 3B, 3C and S3D). The type of cell death, apoptosis or necroptosis, in the paclitaxel-treated A549 cells was identified by observing apoptotic or necrotic features under an electron microscope (Fig 3D).

To extend our notion, we examined the mesenchymal-like and the epithelial-like lung adenocarcinoma cell lines. Paclitaxel was more lethal to the epithelial-like cell lines except for H522 cells which naturally lacked Caspase-8 (Fig. S3E). Nec-1 blocked the paclitaxel-induced cell death of mesenchymal-like cells (Fig 3E), whereas z-IETD-fmk restored the viability of the epithelial-like cells (Fig S3E). With the epithelial-like properties, Caspase-8-deficient H522 cells showed cell death similar to A549 cells transduced with Caspase-8 shRNA (Fig S3E). In addition, autophagy might not influence either cisplatin- or paclitaxel-induced cell death (Fig 3C). Taken together, Caspase-8 phosphorylation or knockdown initiated the necroptosis of lung adenocarcinoma under paclitaxel treatment, whereas the mesenchymal-like A549 cells with control shRNA had the considerable resistance to paclitaxel.

Our previous study revealed that phosphorylated Caspase-8 by c-Src overactivated c-Src to phosphorylate E-cadherin phosphorylated by RNF43-initiated E-cadherin ubiquitination to maintain EMT in lung adenocarcinoma [17]. To dissect the relationship between EMT and resistance to chemotherapy, we stably transfected H522 cells with control vector, Caspase-8 holoprotein or constitutively active c-Src (Src Y527F) (Fig S3I) [21] and A549 cells with control or RNF43 shRNA (Fig S3J), in which H522 cells expressing Caspase-8/Src Y527F and A549 cells with RNF43 knockdown exhibited the mesenchymal-like properties [17]. RNF43 knockdown impaired EMT without influencing the c-Src-Caspase-8 interaction and promoted a marked increase in necroptotic cell death in A549 cell treated with paclitaxel (Fig S3H). Intriguingly, the transfection of Src Y527F and Caspase-8 into H522 cells facilitated EMT and obviously attenuated
paclitaxel-induced cell death (Fig 3K). Collectively, these data suggest that the induction of EMT based on c-Src-Caspase-8 increased the resistance of lung adenocarcinoma to paclitaxel.

**FADD interacted with Caspase-8, c-FLIP and RIPK1 to induce cell death signaling following paclitaxel treatment.**

Next, we determined the molecular mechanisms underlying the antitumor efficiency of paclitaxel. Paclitaxel triggered the apoptotic cleavage of Caspase-8 in c-Src-silenced A549 cells (Fig 4A). After we labeled tumor cells with $[^{32}P]$-orthophosphate, RIPK1, RIPK3 and MLKL were phosphorylated in A549 cells stably transfected with Caspase-8 shRNA treated with paclitaxel (Fig 4A), whereas A549 cells transfected with control shRNA exhibited a reduction in RIPK1, RIPK3, and MLKL phosphorylation (Fig 4A). H522 cells with control vector and ectopic expression of Caspase-8 presented a similar outcome as A549 cells under paclitaxel treatment (Fig S4A). To determine whether RIPK1 activation played an important role in the paclitaxel-induced necroptosis of lung adenocarcinoma, we applied the RIPK1 inhibitor, nec-1 to paclitaxel-treated A549 and H522 cells. Nec-1 was able to block RIPK1/RIPK3/MLKL activation in A549 and H522 cells with Caspase-8 deficiency or phosphorylation (Figs 4B and S4B). In the absence of Caspase-8, c-Src overactivation via the expression of constitutively active c-Src (Src Y527F) in H522 cells exhibiting EMT attenuated the necroptotic RIPK1/RIPK3/MLKL signaling (Fig S4A). Collectively, it was plausible that the mesenchymal state of lung adenocarcinoma cells yielded the resistance to paclitaxel-induced necroptosis.

Previous work elucidated that FADD bound to Caspase-8, cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (long) (c-FLIP) and RIPK1 through death effector domains (DEDs) or the death domain (DD) to trigger alternative cell death pathways, apoptosis or necroptosis [14, 22]. We investigated whether FADD was necessary to induce lung adenocarcinoma cell death through its interaction with Caspase-8, c-FLIP and RIPK1. FADD deletion had no effect on the c-Src-Caspase-8 interaction (Fig 4C). In untreated A549 and H522 cells, Caspase-8 and RIPK1 did not coimmunoprecipitate with FADD, which was accompanied by frequent binding of c-FLIP to FADD (Figs 4D and S4C). Caspase-8 binding to FADD resulted in remarkably decreased c-FLIP binding to trigger apoptotic cell death in the paclitaxel-treated A549 cells transduced with c-Src shRNA (Figs 4D and 4C), whereas p-Casp8 was not bound to FADD in the paclitaxel-treated A549 and H522 cells (Figs 4D and S4C). RIPK1 was significantly increased in the coimmunoprecipitated complex with an antibody specific for FADD in the paclitaxel-treated A549 and H522 cells with deficient or phosphorylated Caspase-8 (Figs 4D and S4C). We next determined how FADD affected paclitaxel-induced cell death. FADD silencing via lentiviral delivery of shRNA (Figs S4D and S4E) was able to rescue A549 and H522 cells from paclitaxel-induced apoptosis or necroptosis (Figs 4E and S4F). FADD silencing proficiently inhibited the phosphorylation of RIPK1, RIPK3 and MLKL in A549 cells transduced with control or Caspase-8 shRNA (Fig 4F) and the apoptotic cleavage of Caspase-8 in A549 cells transduced with c-Src shRNA (Fig S4G). Similarly, FADD knockdown ablated RIPK1/RIPK3/MLKL activation to block the necroptosis of H522 cells (Fig 4G). The antitumor activity of FADD in the paclitaxel-induced cell death was confirmed by in vivo xenograft analysis (Figs S4H and S4I). Taken
together, it's suggested that FADD promoted the paclitaxel-induced cell death of lung adenocarcinoma via the assembly of FADD-c-FLIP-Caspase-8-RIPK1.

To elucidate the role of c-FLIP in paclitaxel-induced cell death, c-FLIP in A549 cells was knocked down with lentiviral shRNA (Fig S4J). Surprisingly, c-FLIP knockdown did not alter the apoptosis and necroptosis in A549 cells (Figs S4J and S4K). In the immunoprecipitated complex using FADD antibody in paclitaxel-treated A549 cells, c-FLIP knockdown did not affect the interaction between RIPK1/Caspase-8 and FADD (Fig S4L). Consistently, c-FLIP knockdown did not affect the paclitaxel-induced H522 cell death (Figs S4M and S4N), while the interaction between FADD and RIPK1/Caspase-8 was not affected by c-FLIP in H522 cells (Fig S4O). These data indicated that c-FLIP might suppress apoptosis in untreated cells and does not affect cell death under paclitaxel treatment.

**IncRNA-related chemotherapy resistance in lung adenocarcinoma (IncCRLA) inhibited RIPK1-induced necroptosis in the mesenchymal-like lung adenocarcinoma.**

Necroptosis was obviously attenuated in the mesenchymal-like lung adenocarcinoma cells under paclitaxel treatment compared with that in the epithelial-like lung adenocarcinoma cells. We explored whether EMT contributed to resistance to paclitaxel in lung adenocarcinoma. An antibody against β-catenin, 7A7, was delivered to block β-catenin nuclear translocation, which inhibits EMT with no effects on the c-Src-Caspase-8 interaction [14]. 7A7 antibody delivery promoted necrotic cell death with RIPK1/RIPK3/MLKL activation in A549 and H522 cells and had no effect on c-Src-induced Caspase-8 phosphorylation (Figs 5A, 5B, and S5A). The transfection of constitutively active c-Src (Src Y527F) into Caspase-8-deficient H522 cells promoted EMT [17] and reduced RIPK1-induced necroptosis (Fig S4A). This finding suggested that EMT in lung adenocarcinoma obviously reduced paclitaxel-triggered necroptotic cell death in lung adenocarcinoma.

Mounting evidence has indicated that lncRNAs are critical for chemotherapy resistance in various human tumors [23, 24]. In an attempt to identify the IncRNA(s) required for EMT-related resistance to paclitaxel in mesenchymal-like lung adenocarcinoma cells, we conducted two sequential rounds of screening (Fig S5B). First, a IncRNA microarray was utilized to compare IncRNA expression profiles between the mesenchymal-like (A549+Control-Mesenchymal) and the epithelial-like (A549+Caspase-8/c-Src shRNA-Epithelial) A549 cells (Fig 5C). The 8 most differentially expressed IncRNAs (fold change >8-fold, Figs 5D, S5C and Table S3) were validated by qRT-PCR in A549 cells and H522 cells (Figs 5E and S5C). Then, selected IncRNAs were subjected to loss-of-function and gain-of-function analyses in the mesenchymal-like and the epithelial-like cells, respectively (Figs S5D and S5F). In the mesenchymal-like A549 cells (A549+Control), of the 8 most differentially expressed IncRNAs, IncRNA 444464 was the only one to increase the sensitivity to paclitaxel when knocked down (Figs 5F and 5G). Notably, IncRNA 444464 failed to rescue paclitaxel-induced death of A549+c-Src shRNA cells (Fig S5E), but was able to obviously decrease paclitaxel-induced death of A549+Caspase-8 shRNA cells (Fig S5G). Therefore, we focused on the uncharacterized IncRNA 444464 (**ENST00000444464**) and named it IncRNA-related chemotherapy resistance in lung adenocarcinoma (IncCRLA). This long-coding RNA was located on chromosome 17 in
humans and 512 ntin length (Fig S5H). The noncoding nature of lncCRLA was confirmed by coding potential analysis (Fig S5I). Consistently, the mesenchymal-like H522 cells (H522+Src Y527F/Caspase-8-Mesenchymal) had a much higher level of lncCRLA than the epithelial-like H522 cells (H522+Control-Epithelial, Fig S5J), and transduction of lncCRLA shRNA efficiently enhanced cell death (Fig 5H). We transfected exogenous lncCRLA into H522 cells, which led to a reduction in cell death (Fig S5K). To dissect the functional role of lncCRLA, we stably overexpressed lncCRLA in Caspase-8-lacking epithelial-like cells via adenoviral transduction and stably knocked down lncCRLA in the p-Casp8-positive mesenchymal-like cells via lentiviral shRNA. lncCRLA blocked RIPK1-induced necroptotic signaling and reduced the number of PI-positive cells in mesenchymal-like A549 and H522 cells (Fig 5I). In the epithelial-like tumor cells, lncCRLA conferred resistance to paclitaxel-induced necroptosis (Fig S5L). Taken together, these data indicated that lncCRLA efficiently hampered paclitaxel-induced necroptotic cell death, but did not affect paclitaxel-induced apoptotic cell death in lung adenocarcinoma.

We sought to determine how lncCRLA influenced paclitaxel-induced necroptosis. It revealed that lncCRLA was predominantly located in the cytoplasm of A549+Control cells (Fig S5M). lncCRLA might function as a competing endogenous RNA to sequester microRNAs (miRNAs) leading to the liberation of corresponding miRNA-targeted transcripts. Subsequent bioinformatics analysis by TargetScan and miRanda showed no putative miRNA response elements. How did lncCRLA impair paclitaxel-mediated RIPK1-induced necroptosis? The radioimmunoprecipitation (RIP) assay showed that lncCRLA interacts with RIPK1 but not RIPK3 in paclitaxel-treated mesenchymal-like tumor cells (Figs 5J and S5N). The RNA pull-down assay confirmed the interaction between RIPK1 and lncCRLA in H522 cells with ectopic lncCRLA expression (Fig S5O). To validate the target domain of RIPK1 for lncCRLA, truncated RIPK1 constructs were created with HA tag (Fig S5P) and stably transfected into the lncCRLA-expressing H522 cells with RIPK1 knockdown via adenoviral shRNA. The functional role of lncCRLA was determined by its binding to the intermediate domain (ID) of RIPK1 independent of the kinase domain (KD) and DD (Fig S5P). It was reasonable that binding of RIPK1 to lncCRLA blocked the RHIM of RIPK1, leading to the inability of RIPK3 to interact with the RHIM of RIPK1 to elicit resistance to paclitaxel in lung adenocarcinoma.

We investigated how lncCRLA was upregulated in the mesenchymal-like lung adenocarcinoma cells. Our previous study revealed that the transcriptional activity of transcription factor 4 (TCF-4) was predominant in inducing the EMT phenotype in lung adenocarcinoma [17]. We hypothesized that TCF-4 functioned as a transcription factor to upregulate lncCRLA. After the promoter region of lncCRLA was reviewed, two Wnt-responsive elements (WRE) were detected between -286 and -292 (5'-CTTTGTG-3') and between -96 and -102 of the transcription start site (TSS) (5'-CTTTGGC-3'). We constructed a set of lncCRLA promoters linked to a luciferase reporter in the mesenchymal-like tumor cells. As shown in Figure 5K, the lncCRLA promoter was able to markedly increase the luciferase activity in the mesenchymal-like lung adenocarcinoma cells, which was confirmed by ChIP assay using an antibody specific for TCF-4 (Fig S5Q).
We next investigated IncCRLA expression and the relationship between IncCRLA and chemotherapy response in patients with lung adenocarcinoma. IncCRLA expression was determined by locked nucleic acid (LNA)-based in situ hybridization (ISH) (Fig 5L) and was significantly increased in patients with resectable and metastatic lung adenocarcinoma who had progressive disease (PD) (Figs 5M and S5R). Moreover, IncCRLA expression was positively correlated with p-Casp8 expression (Fig S5S). Low levels of IncCRLA produced a marked benefit for PFS in the patients with resectable lung adenocarcinoma (Fig S5T). Taken together, these data suggested that upregulation of IncCRLA enhanced chemotherapy resistance of the mesenchymal-like lung adenocarcinoma to paclitaxel by directly binding to RIPK1 to block necroptosis.

c-Src inhibitor, dasatinib and c-FLIP knockdown sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel-induced cytotoxicity.

The prior results indicated that c-Src overactivation via its interaction with phosphorylated Caspase-8 triggered EMT to yield a limited benefit for paclitaxel treatment[17]. Hence, we determined whether the c-Src inhibitor dasatinib could increase the therapeutic benefit of paclitaxel through EMT blockade and Caspase-8 dephosphorylation. Dasatinib was capable of ablating the effects of Caspase-8 phosphorylation and c-Src activation in A549+Control and H522+Caspase-8 (Fig 6A), in which dasatinib efficiently blocked the EMT phenotype and IncCRLA expression (Figs S6A, S6B and S6C). Dasatinib sensitized lung adenocarcinoma cells to paclitaxel (Fig 6B). Surprisingly, the proportion of PI-positive cells increased by approximately 30% in cells treated with paclitaxel plus dasatinib (Fig 6C), while the proportion of Annexin V-positive cells was comparable among the various cell lines (Fig 6C). The contribution of dasatinib to the therapeutic efficacy of paclitaxel in lung adenocarcinoma was confirmed by an in vivo xenograft experiment (Figs 6D and 6E). Consistently, dasatinib enhanced necroptosis by activating RIPK1/RIPK3/MLKL but did not enhance the apoptotic cleavage of Caspase-8 in the mesenchymal-like A549 and H522 cells when combined with paclitaxel (Fig 6F).

Subsequently, we investigated why Caspase-8 dephosphorylation via dasatinib-induced c-Src inactivation did not lead to apoptotic cell death. It was noteworthy that in the paclitaxel-treated A549 and H522 cells, dephosphorylated Caspase-8 induced by dasatinib did not coimmunoprecipitate with FADD, while c-FLIP, an inhibitor of Caspase-8-induced apoptosis, predominantly bound to FADD independent of dasatinib addition (Fig S6D). The interaction between RIPK1 and FADD was strengthened by the addition of dasatinib (Fig S6D). It was more likely that blocking phosphorylated Caspase-8 from binding FADD accounted for the mechanism by which dasatinib-mediated dephosphorylated Caspase-8 could not bind FADD due to c-FLIP occupying the binding pocket.

To explore the influence of c-FLIP on the sensitivity of lung adenocarcinoma to paclitaxel and dasatinib, we constructed 5 siRNAs targeting c-FLIP. According to knockdown efficiency of the siRNAs in A549+Control and H522+Caspase-8 (Figs S6E and S6F), we selected siRNA2 and siRNA4 to construct lentiviral shRNA1 and shRNA2 stably transfected into tumor cells. c-FLIP knockdown markedly promoted the apoptosis of A549 and H522 cells treated with dasatinib plus paclitaxel (Figs 6G, S6G and S6H). c-
FLIP knockdown did not affect RIPK1 activation, but Caspase-8 was recruited to FADD and apoptotically cleaved in both cell lines, in which shRNA1 and shRNA2 of c-FLIP yielded similar effects with different knockdown level of c-FLIP (Figs S6I and S6J). Intriguingly, both c-FLIP shRNA1 and shRNA2 similarly facilitated apoptosis in the A549+c-Src shRNA treated with paclitaxel (Figs S6K and S6L). c-FLIP knockdown by shRNA2 suppressed tumor growth in A549 cells with control shRNA and H522 cells with Caspase-8 in in vivo xenograft experiments (Fig 6H). We observed that c-FLIP shRNA2 did not restrict the therapeutic benefit with a lesser attenuation in c-FLIP expression compared with c-FLIP shRNA1, suggesting that a reduction in c-FLIP expression to some extent was sufficient to sensitize the paclitaxel+dasatinib treatment in lung adenocarcinoma.

Accordingly, we tested the possibility of delivering siRNA targeting c-FLIP combined with paclitaxel liposomes. The paclitaxel liposome plus c-FLIP siRNA (siFLIP) was constructed on the basis of paclitaxel liposomes as a common pharmacological delivery mechanism (Fig 6I). As shown in Figure S6M, paclitaxel liposomes had a great potential to transduce siFLIP into A549 cells. Paclitaxel liposome+siFLIP reduced the mRNA and protein levels of c-FLIP in the mesenchymal-like A549+Control and H522+Caspase-8 cells (Figs 6J and S6N), while paclitaxel liposome+siFLIP combined with dasatinib predominantly eliminated tumor cells in vivo and in vitro (Figs S6O and S6P). Then, we established a patient-derived xenograft (PDX) model to determine the response of lung adenocarcinoma to the combination of paclitaxel liposome+siFLIP and dasatinib. To adequately utilize the patient-derived sample, a PDX model was designed and illustrated in Figure S6Q, and patients involved in the PDX experiment were listed in Table S4. Accordingly, paclitaxel liposome+siFLIP plus dasatinib was significantly superior in inhibiting the growth of tumor cells from patients with resectable lung adenocarcinoma compared with other treatments (Figs 6K and S6R). Collectively, c-FLIP knockdown was able to sensitize the mesenchymal-like lung adenocarcinoma to dual therapies of paclitaxel plus dasatinib.

**Discussion**

During the process of becoming more invasive and motile, cancer cells that have undergone EMT also acquire resistance to several drugs and chemotherapeutic agents [6]. Our prior work showed that the c-Src-Caspase-8 interaction was able to specifically phosphorylate Caspase-8 at tyrosine 380 and overactivate c-Src to facilitate EMT [16]. We generalized our notion that EMT occurred when c-Src-mediated phosphorylation of Caspase-8 overactivated c-Src in a positive feedback loop. It was of major interest that Caspase-8 phosphorylation was ascribed to c-Src expression level in lung adenocarcinoma. Although c-Src is activated by multiple growth and metastatic signaling pathways [25], we determined that phosphorylated Caspase-8 by c-Src played a key role in overactivating c-Src to trigger EMT in lung adenocarcinoma. Our team has focused heavily on the basic activation of c-Src prior to Caspase-8 phosphorylation (data unpublished). Multiple EMT factors and EMT signaling are more pronounced in cancer tissues [26, 27]. Although a plethora of biomarkers have been utilized in the EMT process, Vim and E-cad are likely the best markers in lung adenocarcinoma [15]. We found that p-Casp8-expressing lung adenocarcinoma tissues had the propensity to present with a mesenchymal phenotype with
downregulated E-cad and upregulated Vim and corresponded to a lower response rate to treatment and a worse 5-year PFS. It was rationalized that p-Casp8 was responsible for disease progression arising from the EMT phenotype and chemoresistance in patients with lung adenocarcinoma.

Combined paclitaxel and cisplatin has been the cornerstone for NSCLC treatment for many years; both drugs have completely different mechanisms in eliminating cancer cells[28]. p53 plays a central role in cisplatin-induced cell death [29]. Consistently, our results unveiled that cisplatin killed lung adenocarcinoma cells independent of Caspase-8 and c-Src. In parallel, paclitaxel increased mitotic arrest regardless of Caspase-8 or c-Src as well as markedly induced cell death in a Caspase-8-dependent manner. Thus, we sought to determine whether p-Casp8 might be the lynchpin for EMT-related chemoresistance.

Necroptosis was observed to be a compensatory mechanism under the condition of apoptotic blockade [30, 31]. We detected that phosphorylating Caspase-8 by c-Src or silencing Caspase-8 rescued numerous lung adenocarcinoma cells from cell death but failed to prevent 10-30% necroptotic cell death from paclitaxel. These results implied that Caspase-8 phosphorylation or silencing yielded resistance to paclitaxel due to apoptotic inhibition. Traditionally, paclitaxel, an antimitotic drug, disrupts spindle assembly leading to mitotic arrest by persistent activation of the spindle assembly checkpoint (SAC). Following prolonged arrest, cells either die in mitosis or undergo “slippage,” returning to interphase without completing cell division [32, 33]. More recently, mitotic arrest was reported to lead to DNA damage and genetic instability, which does not give rise to a large number of cell deaths [34, 35]. Our results showed that paclitaxel increased the proportion of cells in mitotic arrest independently of Caspase-8 corresponding to a disproportionately increased amount of cell death dependently of Caspase-8. Therefore, paclitaxel-induced mitotic arrest can be distinguished from its tumoricidal function.

FADD, Caspase-8 and c-FLIP inhibited necroptosis by suppressing RIPK1 and RIPK3 within this complex [36], while FADD-Caspase-8-c-FLIP complex inhibition resulted in the FADD-induced assembly of RIPK1– RIPK3 complex for necroptosis [37, 38]. The assembly of RIPK1-RIPK3 complex via RHIM in response to a variety of stimuli was critical to initiate RIPK1 phosphorylation, which was required for RIPK3-RIPK3 dimerization and RIPK3 phosphorylation, eventually resulting in MLKL phosphorylation to trigger necroptosis [39, 40]. It was approved by our observation that FADD was required to recruit RIPK1 leading to necroptosis and Caspase-8 to induce apoptosis following paclitaxel treatment. These results indicated that FADD functioned as a sensor for cell death stimuli under paclitaxel treatment.

FADD-c-FLIP complex in the absence of Caspase-8 and RIPK1 existed under no treatment. Under paclitaxel stimulation, Caspase-8 replaced c-FLIP and interacted with FADD-involved complex to trigger apoptosis in lung adenocarcinoma cells with unphosphorylated Caspase-8. It was hypothesized that Caspase-8 possesses a higher affinity to FADD relative to c-FLIP under apoptotic stimuli. Caspase-8-c-FLIP based on FADD was reported to inhibit necroptosis by cleaving RIPK1 (at D324) and RIPK3 (at D333) within this complex [37]. Nevertheless, RIPK1 and RIPK3 showed similar expression levels before and after paclitaxel treatment. We found that RIPK1-induced necroptosis was undetectable with the onset of apoptosis in the...
paclitaxel-treated A549 cells with c-Src shRNA. It was postulated that apoptosis still counteracted RIPK1-induced necroptosis by restricting RIPK1 involvement instead of cleaving RIPK1. It was intriguing that knockdown of c-FLIP did not enhance A549 and H522 cell death with paclitaxel treatment. This was attributed to two mechanisms: c-FLIP was replaced by Caspase-8 under apoptotic conditions, while c-FLIP had no influence on necroptosis under necroptotic conditions.

Although Caspase-8 phosphorylation and Caspase-8 deficiency impaired apoptosis under paclitaxel treatment, Caspase-8 phosphorylation induced a smaller amount of necroptotic death than did Caspase-8 deficiency. Caspase-8 phosphorylation by c-Src initiated EMT to protect tumor cells from paclitaxel-induced antitumor activity. This notion was supported by the observation that compared with the mesenchymal-like A549 cells with control shRNA, the epithelial-like A549 cells with RNF43 shRNA presenting c-Src-Caspase-8 interaction had a higher proportion of cells killed via paclitaxel-induced necroptosis. We focused on the contribution of lncRNA to the resistance of lung adenocarcinoma to paclitaxel. After lncRNA microarray profiling, lncCRLA had the most outstanding effects on the resistance to paclitaxel in the mesenchymal-like lung adenocarcinoma by binding to the ID of RIPK1 to interfere with RIPK1-RIPK3 interaction-based necroptosis. The RHIM domain in the ID of RIPK1 was blocked to hamper its interaction with RIKP3. In addition, exogenous lncCRLA expression rescued the Caspase-8-deficient epithelial-like lung adenocarcinoma from necroptosis.

Dasatinib has been characterized as one of the most efficient antagonists for c-Src and has been recently approved for clinical use in acute lymphoblastic leukemia and several solid tumors [41, 42]. Dasatinib did not increase apoptotic cell death through Caspase-8 cleavage but increased necroptosis in lung adenocarcinoma. Mechanistically, FADD was excessively occupied by c-FLIP in cells with Caspase-8 phosphorylation, but phosphorylated Caspase-8 was dissociated from FADD under paclitaxel treatment. Therefore, Caspase-8 dephosphorylation could not trigger apoptotic cleavage due to dephosphorylated Caspase-8 dissociated from FADD. On the other hand, dasatinib facilitated necroptosis by blocking EMT and suppressing lncCRLA expression. We expected the activation of apoptosis and necroptosis to significantly increase antitumor effects in the mesenchymal-like lung adenocarcinoma with p-Casp8. Our team collaborated with the LvYe pharmacy to create paclitaxel liposomes encapsulating siFLIP, which had been verified to function as a strong antitumor agent and combined these liposomes with dasatinib to treat the mesenchymal-like lung adenocarcinoma. It was noteworthy that c-FLIP knockdown to a lesser extent was sufficient to initiate apoptotic function of Caspase-8.

Conclusions

c-Src-mediated Caspase-8 phosphorylation, which is essential for the EMT phenotype through c-Src overactivation in lung adenocarcinoma cell lines. The shift of these cells to the mesenchymal phenotype lead to chemoresistance to cisplatin plus paclitaxel in patients with resectable lung adenocarcinoma, who also have a significantly worse 5-year PFS rate. Cisplatin killed lung adenocarcinoma cells independent of Caspase-8 status, while paclitaxel triggered necroptosis in lung adenocarcinoma cells with Caspase-8 phosphorylation or deficiency, during which FADD interacted with...
RIPK1 via the DD to block RIPK1/RIPK3/MLKL signaling. Furthermore, a brand-new IncRNA, named IncCRLA, was significantly upregulated by TCF-4 and inhibited RIPK1-induced necroptosis in the mesenchymal-like lung adenocarcinoma cells by impairing of RIPK1-RIPK3 interaction via binding to the ID of RIPK1. Dasatinib enhanced necroptosis in paclitaxel-treated lung adenocarcinoma cells that underwent EMT, while c-FLIP knockdown predominantly sensitized mesenchymal-like lung adenocarcinoma to dasatinib + paclitaxel through apoptosis. Together, the c-Src-Caspase-8 interaction initiated the EMT phenotype and chemoresistance by Caspase-8 phosphorylation and chemoresistance-related IncRNA expression, to which treatment with dasatinib plus paclitaxel liposome + siFLIP was lethal (Fig 7).

**List Of Abbreviations:**

Non-small cell lung cancer (NSCLC); Epithelial-mesenchymal transition (EMT); Fas-associated protein with death domain (FADD); cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (long) (c-FLIP); Receptor-interacting serine/threonine-protein kinase 1/3 (RIPK1/3); RIP homotypic interaction motif (RHIM); Mixed lineage kinase domain-like (MLKL); Necrostatin-1 (nec-1); E-cadherin (E-cad); Vimentin (Vim); Phosphorylated Caspase-8 at the tyrosine 380 (p-Casp8); Activated c-Src at the tyrosine 527 (p-Src); Complete response (CR); Partial response (PR); Spindle assembly checkpoint (SAC); Death effector domain (DED); Death domain (DD); Intermediate domain (ID); Kinase domain (KD); Transcription factor 4 (TCF-4); Locked nucleic acid (LNA)-based in situ hybridization (ISH); Chemotherapy resistance in lung adenocarcinoma (IncCRLA); c-FLIP siRNA (siFLIP); tumor growth factor-β (TGF-β); Patient-derived xenograft (PDX); National Cancer Institute (NCI); American Type Culture Collection (ATCC); American Joint Committee on Cancer (AJCC); immunohistochemistry (IHC); fetal bovine serum (FBS); short hairpin RNAs (shRNAs); hemagglutinin (HA); RNA immunoprecipitation assay (RIP assay); Chromatin immunoprecipitation assay (ChIP assay); Propidium iodide (PI).

**Declarations**

**Ethics approval and consent to participate**

The procedures of this study, including 7 references, were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University. The experiments were performed upon receiving written consent from each subject. The study methodologies conformed to the standards set by the Declaration of Helsinki.

**Consent for publication**

All authors approved for paper publication.

**Availability of data and materials**

All data and materials were available when required.
Competing interests
No

Funding
Supported by National Natural Science Foundation of China (No. 81301847 and No. 81872390)

Authors' contributions
Conception and design: Yang Zhao
Administrative support: Shuqun Zhang, Weili Min
Provision of study materials or patients: Yang Zhao, Liangzhang Sun, Xiao Gao, Xiao Gao, Weili Min
Collection and assembly of data: Yang Zhao, Liangzhang Sun, Xiao Gao
Manuscript writing: Yang Zhao
Final approval of manuscript: Yang Zhao

Acknowledgements
No

References:


Tables
<table>
<thead>
<tr>
<th></th>
<th>pY380-Casp8 n (%)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 60</td>
<td>8 (44.4%)</td>
<td>6 (27.3%)</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>&gt; 60</td>
<td>10 (55.6%)</td>
<td>16 (72.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12 (66.7%)</td>
<td>15 (68.2%)</td>
<td>&gt; 0.05</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>6 (33.3%)</td>
<td>7 (31.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>3 (16.7%)</td>
<td>4 (18.2%)</td>
<td>&gt; 0.05</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>5 (27.8%)</td>
<td>5 (22.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>10 (55.5%)</td>
<td>13 (58.8%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphonode</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0-1</td>
<td>7 (38.9%)</td>
<td>9 (40.9%)</td>
<td>&gt; 0.05</td>
<td></td>
</tr>
<tr>
<td>N2-3</td>
<td>11 (61.1%)</td>
<td>13 (59.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pTNM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>4 (22.2%)</td>
<td>9 (40.9%)</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>III-</td>
<td>14 (77.8%)</td>
<td>13 (59.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>12 (66.7%)</td>
<td>16 (72.7%)</td>
<td>&gt; 0.05</td>
<td></td>
</tr>
</tbody>
</table>

Figures
c-Src-induced Caspase-8 phosphorylation was required for EMT in lung adenocarcinoma cell lines. A and B, Immunoblotting analysis of Caspase-8 and c-Src in the mesenchymal-like (A) (A549, H1299, H2030, H23, H2405, H647, H838) and epithelial-like (B) (H522, H1395, H1473, H1573, H920, H1650) lung adenocarcinoma cell lines plated onto fibronectin for 5 days. C, Phase contrast microscopy of A549 + Control/c-Src/Caspase-8 shRNA plated on dish coated with fibronectin over a 5-day period. Scale bars, 50 μm. D, Immunoblotting analysis of p-Casp8, p-Src, Caspase-8, c-Src, Vimentin, E-cadherin and β-actin in the A549 cells with control/c-Src/Caspase-8 shRNA and H522 cells plated onto fibronectin as indicated time. E, Phase contrast microscopy of H1395, H1473, H1573, H920, H1650 cells stably transfected with c-Src plated on dish coated with fibronectin after a 5-day period. Scale bars, 50 μm. F, Immunoblotting analysis of c-Src, p-Src, p-Casp8, E-cadherin, Vimentin, and β-actin in H1395 and H1437 cells stably transfected with adenoviral control vector or c-Src plated onto fibronectin for 2 days. G, Transwell Boyden chamber analysis of H1395 cells stably transfected with adenoviral control vector and c-Src. Mean ± SE from three determinations in a representative assay. *, p< 0.05. Scale bars, 50 μm.
Figure 2

c-Src-induced Caspase-8 phosphorylation was associated with a mesenchymal phenotype and contributed to chemoresistance in lung adenocarcinoma. A, B and C Immunohistochemical stainings for p-Casp8 (A), E-cadherin (B), Vimentin (C) with high magnification (×400). **, p< 0.01. Scale bar, 50μm. D, Response to cisplatin plus paclitaxel of patients with resectable lung adenocarcinoma. **, p< 0.01. E, Kaplan-Meier PFS curve for 109 lung adenocarcinoma patients with p-Casp8(+) or p-Casp8(-) following two neoadjuvant cycles of cisplatin and paclitaxel. p < 0.01.
c-Src-mediated Caspase-8 phosphorylation inhibited cell death of lung adenocarcinoma through the paclitaxel-triggered necroptosis during EMT. A and B, A549 cells with Control/c-Src/Caspase-8 shRNA were treated with cisplatin (50/100/200 μM) (A) or paclitaxel (100/200/300 nM) (B) for 24, 48, 72 hours. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates. C, A549 cells with Control/c-Src/Caspase-8 shRNA was treated with cisplatin (100 μM, upper) or paclitaxel (200 nM, lower) with the addition of DMSO (Control), zIETD-fmk (50 mM), zVAD-fmk (50 mM), nec-1 (10 mM), or 3-MA (25 mM) for 48 hours. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates. *, p< 0.05, **, p< 0.01. D, Electron microscopy of A549 cells with Control/c-Src/Caspase-8 shRNA treated with paclitaxel for 48 h. Representative EM images were shown. E, Mesenchymal-like cell lines, H1299, H2030, H23, H2405, H1647, and H838 were treated with DMSO (Control), paclitaxel (200 nM), paclitaxel+nec-1 (10 mM), and paclitaxel+zIETD-fmk (50 mM) for 48 hours. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates.
Figure 4

FADD interacted with Caspase-8, c-FLIP and RIPK1 to induce cell death signaling following paclitaxel treatment. A, Immunoblotting analysis of Caspase-8, cleaved Caspase-8, RIPK1, RIPK3, MLKL and β-actin in A549 cells with Control/c-Src/Caspase-8 shRNA treated by 200nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cells were labelled with [32P]-orthophosphate. Phosphorylated RIPK1, RIPK3 and MLKL were measured by Cyclone Plus Phosphor Imager. B, A549 cells with Control/Caspase-8 shRNA were treated by 200nM paclitaxel with or without nec-1 for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cells were labelled with [32P]-orthophosphate. Phosphorylated RIPK1, RIPK3 and MLKL were measured by Cyclone Plus Phosphor Imager. C, Immunoblotting analysis of Caspase-8, p-Casp8, c-Src, p-Src, FADD and β-actin in A549 cells with Control/c-Src/Caspase-8/FADD shRNA after 48-hour attachment on the fibronectin-coated dish. D, The immunocomplexes of A549 cells with Control/c-Src/Caspase-8 shRNA treated with or without 200nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish were eluted with antibody against FADD, and whole elution was used to measure Caspase-8, p-Casp8, c-FLIP, and RIPK1. E, A549 cells with Control/ c-Src or Caspase-8 shRNA combined with or without FADD knockdown were treated with 200 nM paclitaxel for 48 hours. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates. Cells were analyzed for Annexin V/PI staining by flow cytometry. All experiments were repeated 3 times with similar results. *, vs. Control, p< 0.05. **, vs. Control, p< 0.01. F and G, Immunoblotting analysis of RIPK1, RIPK3, MLKL and β-actin in the A549 cells with Control/Caspase-8 shRNA (F) and H522 cells with Control/c-Src Y527F/Caspase-8 (G) combined with or without FADD knockdown after 48-hour attachment on the fibronectin-coated dish. Cells were labelled with [32P]-orthophosphate. Phosphorylated RIPK1, RIPK3 and MLKL were measured by Cyclone Plus Phosphor Imager.
Figure 5

IncRNA-related chemotherapy resistance in lung adenocarcinoma (IncCRLA) inhibited RIPK1-induced necroptosis in the mesenchymal-like lung adenocarcinoma. A, Immunoblotting analysis of p-Casp-8 and β-actin in the A549 cells and H522 cells with Caspase-8 treated by 200nM paclitaxel with or without 747 antibody for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cells were labelled with [32P]-orthophosphate. Phosphorylated RIPK1, RIPK3 and MLKL were measured by Cyclone Plus Phosphor Imager. B, The immunocomplexes of A549 cells and H522 cells with Caspase-8 treated by 200nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish were eluted with antibody against FADD, and whole elution was used to measure c-FLIP, Caspase-8, p-Casp8 and RIPK1. C, LncRNA microarray data of the mesenchymal-like (A549+Control) and the epithelial-like (A549+c-Src/Caspase-8 shRNA) cells was presented in a heatmap. D, Most differently expressed lncRNAs between mesenchymal-like (A549+Control) and epithelial-like (A549+c-Src/Caspase-8 shRNA) cells based on lncRNA microarray, > 8 folds. E, Verification of indicated IncRNAs in the mesenchymal-like (M) or epithelial-like (E) A549 cells by qRT-PCR (n = 3). F, Verification of interference efficiency of siRNAs for indicated lncRNAs in A549 cells with Control shRNA by qRT-PCR (n = 3). G, A549 cells with Control shRNA transfected with indicated siRNAs were treated with 200 nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates.* vs. Control, p< 0.05. H, qRT-PCR analysis of IncCRLA in H522 cells with c-Src Y527F/Caspase-8 stably transfected with control or IncCRLA shRNA (left). Tumor cells as indicated were treated with 200 nM paclitaxel for 48 hours. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit (right). Data were represented as mean ± standard deviation of duplicates. *, vs. Control, p< 0.05.**, vs. Control, p< 0.01. I, Immunoblotting analysis of β-actin in A549 cells with Control shRNA and H522 cells with c-Src Y527F/Caspase-8 treated by 200nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cells were labelled with [32P]-orthophosphate. Phosphorylated RIPK1, RIPK3 and MLKL were measured by Cyclone Plus Phosphor Imager (left). Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates (right).**, vs. Control, p< 0.01. J, RIP assay of the enrichment of RIPK1 on IncCRLA relative to IgG in the cytoplasmic
lysates of A549 cells with Control shRNA and H522 cells with c-Src Y527F/Caspase-8 (n = 3). K, Luciferase activity analysis of a set of promoters as indicated transfected into A549 cells with Control shRNA and H522 cells with c-Src Y527F/Caspase-8. **, vs. Control, p < 0.01. L, LNA ISH analysis of IncCRLA with LNA probes in matched lung adenocarcinoma tissues. Representative LNA ISH images were shown. Scale bar, 50 μm. M, qRT-PCR analysis of IncCRLA in the patients with resectable lung adenocarcinoma with CR, PR, SD and PD during neoadjuvant chemotherapy (left). **, vs. CR, p < 0.01. qRT-PCR analysis of IncCRLA in the p-Casp8-positive or negative resectable lung adenocarcinoma during neoadjuvant chemotherapy (right). **, p < 0.01.
c-Src inhibitor, dasatinib and c-FLIP knockdown sensitized the mesenchymal-like lung adenocarcinoma cells to paclitaxel-induced cytotoxicity. A, Immunoblotting analysis of p-Src, c-Src, p-Casp8, Caspase-8 and β-actin in the A549 cells with Control shRNA and H522 cells with Caspase-8 treated by 200nM paclitaxel for 48 hours after 48-hour attachment on the fibronectin-coated dish. B, A549 cells with Control shRNA and H522 cells with Caspase-8 were treated with 200 nM paclitaxel combined with or without dasatinib (20 nM) for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cell viability was
determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates.*, vs. Control, p< 0.05. C, A549 cells with Control shRNA and H522 cells with Caspase-8 were treated with 200 nM paclitaxel combined with or without dasatinib (20 nM) for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cells were analyzed for Annexin V/PI staining by flow cytometry. All experiments were repeated 3 times with similar results. **, vs. Control, p< 0.01. D and E, Nude mice were subcutaneously xenografted with A549 cells with Control shRNA and H522 cells with Caspase-8 (1.0×106 cells) treated intravenously with paclitaxel plus oral vector or Dasatinib (n = 5 per group). Representative bioluminescent images (D), quantification of bioluminescent imaging signal intensities (E). **, vs. Control, p< 0.01. F, Immunoblotting analysis of Caspase-8, Cleaved Caspase-8, RIPK1, RIPK3, MLK and β-actin in the A549 cells with Control shRNA and H522 cells with Caspase-8 treated by 200nM paclitaxel combined with or without Dasatinib (20 nM) for 48 hours after 48-hour attachment on the fibronectin-coated dish. G, A549 cells with Control shRNA and H522 cells with Caspase-8 stably transfected with Control shRNA, c-FLIP shRNA1 and c-FLIP shRNA2 were treated with 200 nM paclitaxel combined with or without dasatinib (20 nM) for 48 hours after 48-hour attachment on the fibronectin-coated dish. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates.**, vs. Control, p< 0.01. H, Nude mice were subcutaneously xenografted with A549 cells with Control shRNA and H522 cells with Caspase-8 stably transfected by c-FLIP shRNA2 (1.0×106 cells) treated with paclitaxel plus dasatinib (n = 5 per group). Quantification of bioluminescent imaging signal intensities. **, vs. Control, p< 0.01. I, Schematic diagram to illustrate the production of paclitaxel liposome+siFLIP. J, Gel electrophoresis of PCR products of lncCRLA and GAPDH in A549 cells with Control shRNA and H522 cells with Caspase-8 treated with control, paclitaxel, paclitaxel liposome and paclitaxel liposome+siFLIP for 48 hours after 48-hour attachment on the fibronectin-coated dish from qRT-PCR. K, Nude mice were subcutaneously xenografted with patient-derived tumors (5 mm in diameter) treated with oral dasatinib plus control, paclitaxel, paclitaxel liposome, paclitaxel liposome+siFLIP. **, p< 0.01.
Figure 7

A schematic diagram of the resistance of the mesenchymal-like lung adenocarcinoma cells to paclitaxel.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• FigureS1.jpg
• TableS1.docx
• TableS3.xlsx
• Supplementarymaterials.doc
• FigureS2.jpg
• TableS2.docx
• FigureS3.jpg
• FigureS4.jpg
• TableS4.xlsx
• FigureS5.jpg
• FigureS6.jpg